ODAN-INDOMETHACIN 100 MG
INDOMETHACIN : 100 MG · DIN 02231800 · ODAN LABORATORIES LTD
Health Canada status: MARKETED
What is ODAN-INDOMETHACIN?
ODAN-INDOMETHACIN 100 MG contains INDOMETHACIN : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02231800, held by ODAN LABORATORIES LTD, supplied as SUPPOSITORY for RECTAL administration. Health Canada currently lists it as marketed, status dated 01-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ODAN-INDOMETHACIN used for?
Symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis, gout, and severe osteoarthritis (including hip). Used when rectal administration is preferred.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ODAN-INDOMETHACIN called?
The same molecule, INDOMETACIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Indocid | Latin | Australia, Bahrain, Saudi Arabia |
| Arthrexin | Latin | Australia, South Africa |
| Betacin | Latin | South Africa |
| ELMETACIN | Latin | Bahrain |
| Elmetacin Solution | Latin | South Africa |
| Famethacin | Latin | South Africa |
| Flamecid | Latin | South Africa |
| INDOCOLLYRE | Latin | Czechia |
| INDYLON | Latin | Bahrain |
| Methocaps | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02231800 |
|---|---|
| Brand name | ODAN-INDOMETHACIN |
| Generic / active ingredient | INDOMETHACIN : 100 MG |
| Manufacturer | ODAN LABORATORIES LTD |
| Strength | 100 MG |
| Dosage form | SUPPOSITORY |
| Route of administration | RECTAL |
| Schedule | Prescription |
| ATC code | M01AB01 INDOMETACIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-May-2025 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02231800 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2231800 |
| Brand name | ODAN-INDOMETHACIN |
| Active ingredient / INN | INDOMETHACIN : 100 MG |
| ATC code | M01AB01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ODAN LABORATORIES LTD |
How is it administered?
100 to 200 mg daily, individually adjusted. 100 mg can be given as 50 mg twice daily or 100 mg at night. Doses >100 mg must be twice daily. Max total daily dose 200 mg.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 not included in snippet), but usually store at room temperature.
How is it supplied?
Boxes of 30, individually wrapped in plastic foil shells.
Which pack is which?
| Strength on the label | 100 MG |
|---|---|
| Dosage form | SUPPOSITORY |
| Route | RECTAL |
| Packaging as described in the monograph | Boxes of 30, individually wrapped in plastic foil shells. |
| Storage | Not explicitly detailed in provided text (Section 11 not included in snippet), but usually store at room temperature. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
CABG surgery peri-operative setting; 3rd trimester pregnancy; breastfeeding; severe heart failure; hypersensitivity to drug/NSAIDs; active GI ulcer/bleeding; bleeding disorders; IBD; severe liver/renal impairment.
Warnings and precautions
Risk of serious cardiovascular thrombotic events (MI, stroke); serious GI toxicity (bleeding, ulceration, perforation); potential for fluid retention and edema.
What can be used instead?
Other Canadian products sharing ATC code M01AB01 INDOMETACIN. 7 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-INDOMETHACIN | 50 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02499223 |
| MINT-INDOMETHACIN | 25 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02461811 |
| MINT-INDOMETHACIN | 50 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02461536 |
| ODAN-INDOMETHACIN | 50 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02231799 |
| TEVA-INDOMETHACIN | 25 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00337420 |
| TEVA-INDOMETHACIN | 50 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00337439 |
| APO-INDOMETHACIN | 25 MG | CAPSULE | APOTEX INC | DORMANT | DIN 00611158 |
| APO-INDOMETHACIN | 50 MG | CAPSULE | APOTEX INC | DORMANT | DIN 00611166 |
| FTP-INDOMETHACIN | 25 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238442 |
| FTP-INDOMETHACIN | 50 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238443 |
Who else supplies INDOMETACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INDOMETACIN appears in 74 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does INDOMETACIN cost around the world?
INDOMETACIN is listed on 10 national price registers Nexara tracks, across 58 pack listings published on 9 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 16 | 18 | 01 Sep 2026 |
| South Africa | single exit price | 10 | 14 | 01 Sep 2026 |
| Australia | ex-manufacturer | 2 | 8 | 08 Sep 2026 |
| Romania | max producer price | 6 | 8 | 03 Sep 2026 |
| Bahrain | retail (max) | 3 | 3 | 01 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Luxembourg | reimbursement | 2 | 2 | 05 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Czechia | max producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.